Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 1, 2015, Pages 152-163

  Maffione, Anna Margherita ^a   Lopci, Egesta ^b   Bluemel, Christina ^c   Giammarile, Francesco ^d   Herrmann, Ken ^c   Rubello, Domenico ^a  

^a SM Misericordia Hospital   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Colorectal cancer; CT; FDG; Liver metastasis; Management; Meta analysis; MRI; PET; Systematic review; US

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER PATIENT; CANCER STAGING; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINGENCY TABLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; COLORECTAL TUMOR; DIAGNOSTIC USE; LIVER TUMOR; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING; SECONDARY;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84912046409     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2930-4     Document Type: Review

References (37)

1. Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154.
2. Kew MC. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. In: Feldman M, Friedman LS, Sleisenger MH, Scharschmidt BF, editors. Hepatic tumors and cysts. 7th ed. Philadelphia: Saunders; 2002.
3. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al.; European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.
4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network. COL-B, page 2
5. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.
6. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31(1):19–31.
7. Kekelidze M, D’Errico L, Pansini M, Tyndall A, Hohmann J. Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol. 2013;19(46):8502–14.
8. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480–508.
9. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50(7):1036–41.
10. Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014;311(18):1863–9.
11. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.
12. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
13. Coenegrachts K, De Geeter F, ter Beek L, Walgraeve N, Bipat S, Stoker J, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol. 2009;19(2):370–9.
14. Huguet EL, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology. 2007;54(78):1667–71.
15. Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, et al. Contrast-enhanced FDG-PET/CT vs SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol. 2007;48(4):369–78.
16. Bacigalupo L, Aufort S, Eberlé MC, Assenat E, Ychou M, Gallix B. Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT. Radiol Med. 2010;115(7):1087–100.
17. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, et al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis. 2009;11(5):464–9.
18. Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2007;34(12):1906–14.
19. Ramos E, Valls C, Martinez L, Lladó L, Torras J, Ruiz S, et al. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT? Ann Surg Oncol. 2011;18(9):2654–61.
20. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240(6):1027–34.
21. Briggs RH, Chowdhury FU, Lodge JP, Scarsbrook AF. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol. 2011;66(12):1167–74.
22. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg. 2006;141(12):1220–6.
23. Sørensen M, Mortensen FV, Høyer M, Vilstrup H, Keiding S; Liver Tumour Board at Aarhus University Hospital. FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. Scand J Surg. 2007;96(3):209–13.
24. Engledow AH, Skipworth JR, Pakzad F, Imber C, Ell PJ, Groves AM. The role of 18FDG PET/CT in the management of colorectal liver metastases. HPB (Oxford). 2012;14(1):20–5.
25. Bonanni L, De’liguori Carino N, Deshpande R, Ammori BJ, Sherlock DJ, Valle JW, et al. A comparison of diagnostic imaging modalities for colorectal liver metastases. Eur J Surg Oncol. 2014;40(5):545–50.
26. Lake ES, Wadhwani S, Subar D, Kauser A, Harris C, Chang D, et al. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis. Ann R Coll Surg Engl. 2014;96(3):211–5.
27. Cantwell CP, Setty BN, Holalkere N, Sahani DV, Fischman AJ, Blake MA. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr. 2008;32(5):738–44.
28. Carnaghi C, Tronconi MC, Rimassa L, Tondulli L, Zuradelli M, Rodari M, et al. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Nucl Med Rev Cent East Eur. 2007;10(1):12–5.
29. Rojas Llimpe FL, Di Fabio F, Ercolani G, Giampalma E, Cappelli A, Serra C, et al. Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. Br J Cancer. 2014;111(4):667–73.
30. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol. 2011;46(9):548–55.
31. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.
32. van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13.
33. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41(7):1177–89.
34. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104(12):2658–70.
35. Petersen RK, Hess S, Alavi A, Høilund-Carlsen PF. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging. 2014;4(5):471–82.
36. Yang Y, Czernin J. Contribution of imaging to cancer care costs. J Nucl Med. 2011;52 Suppl 2:86S–92S.
37. Siepe B, Hoilund-Carlsen PF, Gerke O, Weber WA, Motschall E, Vach W. The move from accuracy studies to randomized trials in PET: current status and future directions. J Nucl Med. 2014;55(8):1228–34.